Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Dec;94(49):e2133.
doi: 10.1097/MD.0000000000002133.

Prognostic Role of Glasgow Prognostic Score in Patients With Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis

Mu-Xing Li  1 , Xin-Yu Bi, Zhi-Yu Li, Zhen Huang, Yue Han, Jian-Guo Zhou, Jian-Jun Zhao, Ye-Fan Zhang, Hong Zhao, Jian-Qiang Cai
Affiliations
Free PMC article
Review

Prognostic Role of Glasgow Prognostic Score in Patients With Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis

Mu-Xing Li et al. Medicine (Baltimore). 2015 Dec.
Free PMC article

Abstract

Conflicting results about the prognostic value of Glasgow Prognostic Score (GPS) in hepatocellular carcinoma (HCC) patients have been reported. We searched the available articles and performed the meta-analysis to clarify the predictive value of GPS in HCC patients' outcome.A systematic literature search was conducted using PubMed (Medline), Embase, Cochrane Library, Web of Science, ChinaInfo, and Chinese National Knowledge Infrastructure for all years up to September 2015. Studies analyzing the relationship of GPS and survival outcome were identified. Hazard ratio (HR) with 95% confidence interval (CI) was calculated to assess the risk.A total of 10 studies were finally enrolled in the meta-analysis. The pooled estimates demonstrated a significant relationship between elevated GPS and inferior overall survival in patients with HCC (HR = 2.156, 95% CI: 1.696-2.740, P < 0.001). Patients with increased GPS had a tendency toward shorter progression-free survival (HR = 1.755, 95% CI: 0.943-3.265, P = 0.076). And elevated GPS was found to be significantly associated with advanced Child-Pugh class (odds ratio = 25.979, 95% CI: 6.159-109.573, P < 0.001). The publication bias analysis revealed that there was publication bias in the meta-analysis.Glasgow Prognostic Score may be an independent prognostic factor in patients with HCC. More well-designed studies with adequate follow-up duration are warranted.

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

FIGURE 1
FIGURE 1
Flow chart describing the selection of eligible articles.
FIGURE 2
FIGURE 2
Forest plot of hazard ratio for the association between elevated Glasgow Prognostic Score and overall survival in patients with hepatocellular carcinoma with random effects model.
FIGURE 3
FIGURE 3
Forest plot of hazard ratio for the association between elevated Glasgow Prognostic Score and progression-free survival in patients with hepatocellular carcinoma with random effects model.
FIGURE 4
FIGURE 4
A, Forest plot of odds ratio for the association between elevated Glasgow Prognostic Score and Child–Pugh class (Child–Pugh class B and C versus Child–Pugh class A). B, Tumor number (multiple versus solitary). C, Status of hepatitis B surface antigen (positive versus negative). D, Status of hepatitis C virus antibody (positive versus negative) in patients with hepatocellular carcinoma with random effects model.
FIGURE 5
FIGURE 5
Funnel plot for elevated Glasgow Prognostic Score and overall survival in patients with hepatocellular carcinoma.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by 28 articles

See all "Cited by" articles

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA: Cancer J Clin 2015; 65:5–29. - PubMed
    1. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010; 17:1471–1474. - PubMed
    1. Forner A, Reig ME, de Lope CR, et al. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis 2010; 30:61–74. - PubMed
    1. Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985; 56:918–928. - PubMed
    1. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998; 28:751–755. - PubMed